Transaction #28821 · Form 4 · 0002156611-26-000010
aTYR PHARMA INC · Stock award · Employee Stock Option (right to buy)
aTYR PHARMA INC · Transacted October 1, 2026 · Filed October 1, 2026
What does this filing report?
An SEC Form 4 filing for aTYR PHARMA INC records a stock award involving Employee Stock Option (right to buy) on October 1, 2026. The reported quantity was 410,000. The filing date is October 1, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- aTYR PHARMA INC
- Company CIK
- 0001339970
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 410,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 410,000
- Ownership description
- Not reported
- SEC acceptance time
- Oct 1, 2026, 4:03 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Yaras Brandon ↗
Chief Financial Officer
CIK 0002156611
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 410,000
- Conversion / exercise price
- 0.3
- Exercise date
- Not reported
- Expiration date
- October 1, 2036
Filing footnotes & remarks
- F1
- The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning November 1, 2026, such that this option will be fully exercisable on November 1, 2030. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.